Breast cancer remains a leading cause of morbidity and mortality among women worldwide, with emerging evidence underscoring the microbiota’s pivotal role in its etiology, progression, and therapeutic response. This narrative review synthesizes the intricate interplay between the breast tissue, skin, and lung microbiomes in breast cancer pathogenesis, with particular emphasis on inflammatory breast cancer (IBC) and metastatic dissemination. The healthy breast microbiome, dominated by Firmicutes, Proteobacteria, Actinobacteria, and Bacteroidetes, maintains tissue homeostasis through pH regulation, metabolite production, and immune modulation. Dysbiosis disrupts this equilibrium, fostering carcinogenesis via chronic inflammation, estrogen deconjugation, and DNA damage-induced genomic instability, with subtype-specific microbial signatures influencing tumor growth and therapy resistance. In IBC, skin microbiome alterations characterized by overgrowth of pathogens like Pseudomonas aeruginosa and Staphylococcus aureus exacerbate inflammation, epithelial-mesenchymal transition (EMT), and lymphatic invasion, while promoting a pro-tumorigenic microenvironment enriched in regulatory T cells and M2 macrophages. Concurrently, lung microbiota dysbiosis impairs immune surveillance, remodels the extracellular matrix, and facilitates metastatic seeding through neutrophil extracellular traps and cytokine storms. Cross-talk among these microbiomes amplifies systemic effects, highlighting their synergistic contributions to disease aggressiveness. Advanced analytical techniques, including 16S rRNA sequencing, metagenomics, and metabolomics, offer promising microbial biomarkers for early detection and risk stratification. By elucidating these host-microbe dynamics, this review advocates for microbiome-centric interventionssuch as probiotics, fecal microbiota transplantation, and targeted antimicrobials to enhance precision diagnostics and therapies, ultimately improving outcomes in breast cancer management.

The surge in monkeypox (mpox) cases has generated global concern. An unexpected outbreak in May 2022 spread rapidly, driven by clade IIb, predominantly affecting men who have sex with men. As of mid-2024, over 120 countries reported mpox cases, with 100,000 confirmed cases and 220 deaths, leading WHO to declare two PHEICs. In Pakistan, since April 2023, 11 cases and one death were recorded, primarily in Khyber Pakhtunkhwa, highlighting challenges in diagnostic testing and public awareness. Efforts by the Ministry of Health focus on surveillance and education, but enhanced strategies are needed. These include improved surveillance, healthcare workers' training, international collaboration, and vaccination programs. Addressing these gaps is crucial for effective containment and prevention of further spread.

Purpose of Review: Pediatric airway management in the Emergency Department is a critical intervention with high stakes and significant complication rates, including adverse events in 16–25% of intubations and first-attempt success rates of approximately 75%. This review examines the application of advanced digital technologies—artificial intelligence (AI), machine learning (ML), computer vision, deep learning, and predictive analytics—to address key gaps: unreliable prediction of difficult pediatric airways (with first-pass failure rates of 30–40%), variability in device selection and technique, and the absence of robust real-time decision support for clinicians. Recent Findings: Emerging AI tools demonstrate promise across three phases of airway management. For prediction, machine learning models analyzing patient data can identify difficult airways with accuracy approaching that of expert clinicians. During performance, deep learning algorithms applied to video laryngoscopy automatically recognize anatomical landmarks (e.g., vocal cords) and guide laryngoscope positioning, improving visualization and potentially first-attempt success. For monitoring, AI-based systems analyze real-time physiological signals - including heart rate, oxygen saturation, and respiratory patterns - to detect subtle signs of airway difficulty or patient decompensation, showing improved hypoxia detection compared to standard monitoring. Summary: Integrating AI and advanced technologies could enable a future of “precision airway management,” tailoring interventions to individual patient anatomy, physiology, and risk factors to reduce failed intubations and complications. Realizing this potential requires ensuring equitable access to avoid disparities between centers, mitigating algorithmic bias, and fundamentally incorporating AI education—covering advanced airway technologies and human-AI collaboration—into Pediatric Emergency Medicine and anesthesia training programs.

Introduction and importance: Yellow nail syndrome (YNS) is a rare disorder diagnosed by a triad of yellowish-green discoloration of the nails, respiratory manifestations, and lymphedema. Kartagener’s syndrome (KS) is an autosomal recessive syndrome characterized by chronic sinusitis, bronchiectasis, infertility, and situs inversus. In this case we report the rare coexistence of these solitary occurring disorders. Case presentation: This report details an interesting case wherein the clinical manifestation of YNS in a 54-year-old male patient not only led to its diagnosis but also revealed the coexistence of another distinctive underlying genetic disorder – KS. Clinical discussion: KS is an autosomal recessive syndrome characterized by chronic sinusitis, bronchiectasis, infertility, and situs inversus. While KS and YNS are two discernibly unique syndromes, the simultaneous clinical manifestation of their pathologies within a single patient, as presented in our patient, is notably infrequent and rare. Conclusion: While there is significant documented evidence of YNS co-occurring with only bronchiectasis, we present this case due to the rarity of the amalgamation of YNS with the complete spectrum of pathologies associated with KS. This may help in early diagnosis of either disorder via investigation on the basis of their coexistence as presented in this case and may result in better health outcomes in clinical practice.

Ozempic (semaglutide) was first authorized to treat type 2 diabetes, but because of its appetite-suppressing properties, it has become popular off-label for weight loss. According to clinical investigations, GLP-1 significantly decreases blood sugar and helps people lose weight. Approximately 15 million persons in the United States are currently taking GLP-1 drugs. Off-label use is becoming more common, which raises worries about potential health hazards and significant side effects such as non-arteritic anterior ischemic optic neuropathy (NAION). According to a study, 6.7% of people who were overweight and 8.9% of those with diabetes who took semaglutide had NAION. The FDA issued a warning regarding counterfeit and compounded products while approving semaglutide for weight loss under the Wegovy ^® brand. Unsupervised usage and problems with diabetes accessibility raise ethical questions.

Gastrointestinal obstruction is an important cause of morbidity and mortality in the United States, but full descriptions of time trends and disparities are poorly defined. This study aims to examine trends in mortality from gastrointestinal obstruction over a span of 25 years in various demographics and geographic locations within the United States from 1999 to 2023. We conducted a retrospective analysis using CDC WONDER multiple cause-of-death data. Deaths were identified when gastrointestinal obstruction was listed as either the underlying or a contributing cause of death. Age-adjusted mortality rates (AAMR) per 1,00,000 population were calculated and stratified by sex, race/ethnicity, census region, urbanization level, and state. Joinpoint regression analysis identified inflection points and estimated annual percent changes (APC) and average annual percent changes. Between 1999 and 2023, 5,20,045 deaths from gastrointestinal obstruction were identified. Overall, AAMR declined from 10.76 per 1,00,000 in 1999 to 8.56 in 2014, followed by an increase to 9.95 in 2023. Joinpoint analysis revealed 3 distinct phases: significant decline (1999–2012, APC −1.78%, P < .001), plateau (2012–2018, APC −0.09%, P = .862), and significant increase (2018–2023, APC 3.43%, P < .001). Males consistently exhibited higher mortality than females throughout the study period (2023: 10.44 vs 9.59 per 1,00,000). Substantial racial disparities persisted, with non-Hispanic Black individuals demonstrating the highest AAMR (12.95 in 2023), 1.32-fold higher than non-Hispanic white individuals. Rural areas maintained consistently higher mortality than urban areas; data from 2020 are presented for urbanization comparisons, as this was the most recent year with complete rural-urban classification data available from CDC WONDER at the time of analysis (2020: 10.99 vs 8.54 per 1,00,000). State-level age-adjusted mortality rates varied nearly 2-fold, ranging from 6.86 in Florida to 13.15 in Vermont. Most deaths occurred in medical facilities (66.8%). After a decade of declining gastrointestinal obstruction mortality, rates have increased significantly since 2018 across nearly all demographic groups. Persistent disparities by race, geography, and urbanization underscore the need for targeted interventions and equitable access to timely surgical care. The reversal of favorable trends warrants urgent investigation into contributing factors and implementation of prevention strategies.